Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Advisory Panel Supports NeuroPace’s RNS Neurostimulator

This article was originally published in The Gray Sheet

Executive Summary

Neurological devices panel votes in favor of device intended to reduce epileptic seizures despite lingering questions about the trial results.

You may also be interested in...



Six Devices, Diagnostics Among Cleveland Clinic’s Top 10 Innovations For 2014

At its October Medical Innovation Summit, the Cleveland Clinic unveiled six device and diagnostics products that were selected for inclusion in its list of top 10 innovations for 2014.

NeuroPace’s RNS For Epilepsy Becomes First FDA-Approved Responsive Neurostimulator

While standard neurostimulators are open-loop systems that stimulate continuously or intermittently according to preprogramming, RNS is a more targeted, closed-loop system that monitors brain activity in real time and provides electrical stimulation to interrupt troubling patterns that might cause a seizure.

NeuroPace’s RNS For Epilepsy Becomes First FDA-Approved Responsive Neurostimulator

While standard neurostimulators are open-loop systems that stimulate continuously or intermittently according to preprogramming, RNS is a more targeted, closed-loop system that monitors brain activity in real time and provides electrical stimulation to interrupt troubling patterns that might cause a seizure.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT032762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel